Repare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023 [Yahoo! Finance]
Repare Therapeutics Inc. - Common Shares (RPTX)
Company Research
Source: Yahoo! Finance
Net Loss : Increased net loss to $28.0 million in Q4 and $93.8 million for the full year. Research and Development Expenses : R&D expenses rose to $35.3 million in Q4 and $133.6 million for the full year. General and Administrative Expenses : G&A expenses slightly increased to $8.6 million in Q4 and $33.8 million for the full year. Liquidity Position : Cash, cash equivalents, and marketable securities totaled $223.6 million as of December 31, 2023. Operational Milestones : Advanced clinical programs and received a $40 million milestone payment from Roche. Collaboration Termination : Roche to terminate collaboration agreement with Repare in May 2024. Warning! GuruFocus has detected 4 Warning Signs with RPTX. On February 28, 2024, Repare Therapeutics Inc ( NASDAQ:RPTX ) released its 8-K filing , detailing the financial results for the fourth quarter and the full year ended December 31, 2023. The precision oncology company, which specializes in developing synthetic lethali
Show less
Read more
Impact Snapshot
Event Time:
RPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPTX alerts
High impacting Repare Therapeutics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
RPTX
News
- Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of DirectorsBusiness Wire
- Repare Therapeutics Inc.'s (NASDAQ:RPTX) market cap dropped US$21m last week; Private equity firms bore the brunt [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics Inc. (NASDAQ: RPTX) was upgraded by analysts at Bloom Burton from an "accumulate" rating to a "buy" rating.MarketBeat
- Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
- Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
RPTX
Earnings
- 2/28/24 - Miss
RPTX
Sec Filings
- 4/26/24 - Form 8-K
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- RPTX's page on the SEC website